Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis

Yanagisawa, Takafumi; Rajwa, Paweł; Thibault, Constance; Gandaglia, Giorgio; Mori, Keiichiro; Kawada, Tatsushi; Fukuokaya, Wataru; Shim, Sung Ryul; Mostafaei, Hadi; Motlagh, Reza Sari; Quhal, Fahad; Laukhtina, Ekaterina; Pallauf, Maximilian; Pradère, Benjamin; Kimura, Takahiro; Egawa, Shin; Shariat, Shahrokh F.

doi:10.1016/j.eururo.2022.08.002

Cited by 53 publications

(47 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Third, despite the importance of benefit-harm and QOL assessment considering AEs, it was not assessed in the current study as we previously published AE outcomes. 14 Finally, while the triplet combination therapy has gained increasing attention owing to the positive results of several RCTs and network meta-analysis, [34][35][36] we only assessed the impact of doublet therapy on survival in real-world practice. Based on our results, one could hypothesize that the efficacy of sequential therapy after triplet therapy is likely to be more limited than that of doublet therapy.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. Methods:The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd-and 3rd-line PFS, were compared. We used one-to-two propensity score matching to minimize the confounders. The differential efficacy of 2nd-line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest.Results: After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3-year OS and CSS for DOC versus ABI were 76.2% versus 75.1% (p = 0.8) and 78.2% versus 78.6% (p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd-line PFS (14 vs. 4 months, p < 0.001) and 3rd-line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd-line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd-line therapy (both 3 months, p = 0.8).Conclusions: ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC,

show abstract

Section: Discussionmentioning

confidence: 99%

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hier konnte unsere Arbeitsgruppe nach Pooling aller verfügbaren Doublet-und Triplet-Therapien zeigen, dass die Triplet-Therapie aus ADT + Abirateron + Docetaxel dem der Doublet-Therapie mit den besten OS-Outcomes (ADT + Abirateron) beim Highvolume-mHSPC überlegen sein könnte (HR für das OS 0,52 vs. 0,61; [12]). Zu nahezu selben Schlüssen kommen methodisch ähnliche Reviews und Network-Metaanalysen anderer Arbeitsgruppen [15][16][17][18].…”

Section: High-volume-metastasierungunclassified

Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer

et al. 2023

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Nachdem die alleinige Androgendeprivationstherapie (ADT) lange Zeit die Goldstandardbehandlung des metastasierten hormonsensitiven Prostatakarzinoms (mHSPC) war, wurde diese in den letzten Jahren durch Doublet-Kombinationstherapien aus ADT + erweiterte Hormontherapie (ARTA, „androgen receptor targeted agent“) oder ADT + Docetaxel-Chemotherapie abgelöst. Erstmals stehen nun Daten aus Triplet-Kombinationstherapien aus ADT + ARTA (Abirateron/Darolutamid) + Docetaxel-Chemotherapie zur Verfügung. Fragestellung Welcher mHSPC-Patient profitiert von einer „Doublet“- vs. „Triplet-Kombinationstherapie“ und welches Nebenwirkungsspektrum ist jeweils zu erwarten? Ergebnisse Die aktuellen Triplet-Therapien (ADT + Docetaxel + Abirateron/Darolutamid) zeigen eine Verlängerung des Gesamtüberlebens gegenüber der Doublet-Therapie aus ADT + Docetaxel aller mHSPC (ARASENS) bzw. primär metastasierten „High-volume-“ (PEACE-1) mHSPC-Patienten. Im Setting des High-volume-mHSPC zeigt sich dieser positive Gesamtüberlebenseffekt explizit für die Triplet-Kombination aus ADT + Docetaxel + Abirateron. Beim Low-volume-mHSPC zeigt sich dieser Effekt lediglich für das progressionsfreie Überleben – jedoch nicht für das Gesamtüberleben. Ähnliche Darolutamid‑/Triplet-Kombinationstherapie’ Daten (High- vs. Low-volume-mHSPC) liegen aktuell nicht vor. Die Nebenwirkungsraten von „Triplet- vs. Doublet-Kombinationstherapie“ sind nur leicht erhöht und v. a. auf typische Chemotherapie-assoziierte (Neutropenie) und Androgenrezeptorantagonisten (ARTA)-spezifische Nebenwirkungen (Abirateron) zurückzuführen. Zusammenfassung Die ADT-Mono- und die „Doublet-Kombinationstherapie“ aus ADT + Docetaxel sollten in der Erstlinientherapie beim mHSPC keine Rolle mehr spielen. Bis zum Vorliegen weiterführender Daten über den Zusatznutzen der „Triplet-Kombinationstherapie“ in relevanten Subgruppen, stellen die Kombinationstherapien aus ADT + ARTA bzw. ADT + ARTA + Docetaxel in Abhängigkeit patientenspezifischer Charakteristika (Alter, ECOG [Eastern Cooperative Oncology Group], Metastasenlast, primäre/sekundäre Metastasierung) die aktuelle primären Therapieoptionen dar.

show abstract

“…Figure 20: Risk of Bias Assessment of the Included RCTs (Yanagisawa et al� [2022]) ��100…”

Section: List Of Figuresunclassified

“…Outcomes of interest included OS, time to CRPC, and radiographic progression-free survival (rPFS). 8 Two additional NMAs were identified in the CADTH literature search (Menges et al [2022], Yanagisawa et al [2022]). 9,10 The objective of the published SLR and NMA by Menges et al was to assess the clinical effectiveness regarding survival and HRQoL, safety, and benefit-harm balance of metastatic hormone-sensitive prostate cancer (mHSPC) treatments, including docetaxel, abiraterone, enzalutamide, apalutamide, darolutamide, and radiotherapy (alone or in combination with ADT) via frequentist, random-effects NMA.…”

Section: Description Of Studiesmentioning

confidence: 99%

Darolutamide (Nubeqa)

CADTH¹

2023

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses darolutamide (Nubeqa), 300 mg, tablet, for oral use. Indication: The treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

show abstract

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis

Cited by 53 publications

References 39 publications

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer

Darolutamide (Nubeqa)

Contact Info

Product

Resources

About

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis

Cited by 53 publications

References 39 publications

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer

Darolutamide (Nubeqa)

Contact Info

Product

Resources

About

Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer